Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
AIM ImmunoTech
(AMEX:AIM)
Intraday
$0.43
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$0.43
0
[0.00%]
At close: Apr 24
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for AIM ImmunoTech Stock (AMEX:AIM)
AIM ImmunoTech Stock (AMEX: AIM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 10, 2024
AIM ImmunoTech Announces Top-Line, Protocol-Planned Interim Report Data From Study Of Ampligen Combined With Pembrolizumab For Recurrent Ovarian Cancer
Benzinga Newsdesk
-
Apr 10, 2024, 8:22AM
Tuesday, April 02, 2024
AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate
Benzinga Newsdesk
-
Apr 2, 2024, 10:58PM
AIM ImmunoTech Reported Cash, Cash Equivalents And Marketable Investments Of $13.1M, As Of December 31, 2023
Benzinga Newsdesk
-
Apr 2, 2024, 7:34AM
Earnings Scheduled For April 2, 2024
Benzinga Insights
-
Apr 2, 2024, 6:25AM
Monday, April 01, 2024
Preview: AIM ImmunoTech's Earnings
Benzinga Insights
-
Apr 1, 2024, 2:05PM
Tuesday, March 26, 2024
Earnings Scheduled For March 26, 2024
Benzinga Insights
-
Mar 26, 2024, 4:47AM
Monday, March 25, 2024
AIM ImmunoTech Announces Publication Of Findings From Study Evaluating Ampligen In Treatment Of Pancreatic Cancer In Journal Clinical Cancer Research
Benzinga Newsdesk
-
Mar 25, 2024, 9:10AM
AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying
Avi Kapoor
-
Mar 25, 2024, 6:33AM
Thursday, March 07, 2024
AIM ImmunoTech Launches CEO Corner Platform
Benzinga Newsdesk
-
Mar 7, 2024, 8:46AM
Wednesday, February 14, 2024
AIM ImmunoTech Announces First Subject Dosed In Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For Pancreatic Cancer
Benzinga Newsdesk
-
Feb 14, 2024, 8:56AM
Monday, February 12, 2024
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
Feb 12, 2024, 4:30PM
Thursday, February 08, 2024
AIM ImmunoTech Reports Topline Results From Phase 2 Study Evaluating Ampligen For Treatment Of Post-COVID Conditions
Benzinga Newsdesk
-
Feb 8, 2024, 8:52AM
Wednesday, January 24, 2024
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen For Treatment Of Locally Advanced Pancreatic Cancer
Benzinga Newsdesk
-
Jan 24, 2024, 9:12AM
Tuesday, January 23, 2024
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Jan 23, 2024, 4:31PM
Monday, January 22, 2024
AIM ImmunoTech Announces That The First Subject Is Enrolled In The Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For The Treatment Of Late-Stage Pancreatic Cancer
Benzinga Newsdesk
-
Jan 22, 2024, 8:55AM
Thursday, January 11, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jan 11, 2024, 8:05AM
Wednesday, January 10, 2024
AIM ImmunoTech Announces Open Enrollment For Phase 1b/2 Study Evaluating Ampligen With AstraZeneca's Imfinzi For Pancreatic Cancer Treatment
Benzinga Newsdesk
-
Jan 10, 2024, 8:46AM
Wednesday, January 03, 2024
Kellner Group Issued Statement In Connection With Their Efforts To Bring Accountability To The AIM ImmunoTech Board Of Directors
Benzinga Newsdesk
-
Jan 3, 2024, 4:16PM
Friday, December 29, 2023
AIM ImmunoTech Says Delaware Court Rules In Favor Of Company, Upholds Board's Determination That Activist Group's Nominations Are Invalid
Benzinga Newsdesk
-
Dec 29, 2023, 8:07AM
Tuesday, November 28, 2023
AIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buying
Lisa Levin
-
Nov 28, 2023, 6:39AM
Monday, November 27, 2023
AIM ImmunoTech Issued Two US Patents Titled 'Compositions for cancer therapy and methods' And 'Methods for improving exercise tolerance in myalgic encephalomyelitis patients'
Bill Haddad
-
Nov 27, 2023, 9:06AM
Tuesday, November 21, 2023
AIM ImmunoTech Completes Treatment Of Last Subject In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions
Benzinga Newsdesk
-
Nov 21, 2023, 12:01PM
Wednesday, November 15, 2023
Earnings Scheduled For November 15, 2023
Benzinga Insights
-
Nov 15, 2023, 7:30AM
AIM ImmunoTech Q3 EPS $(0.16) Misses $(0.11) Estimate, Sales $46.00K Beat $20.00K Estimate
Benzinga Newsdesk
-
Nov 15, 2023, 7:23AM
Tuesday, November 14, 2023
Preview: AIM ImmunoTech's Earnings
Benzinga Insights
-
Nov 14, 2023, 12:00PM
AIM ImmunoTech Announces Publication Of Data From Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen As A Component Of A Chemokine-Modulating Regimen In Metastatic Triple-Negative Breast Cancer
Benzinga Newsdesk
-
Nov 14, 2023, 10:06AM
Wednesday, November 08, 2023
AIM ImmunoTech Announces Translational Data From Phase 2 Study Evaluating Ampligen For The Treatment Of Advanced Recurrent Ovarian Cancer
Benzinga Newsdesk
-
Nov 8, 2023, 8:47AM
Monday, November 06, 2023
AIM ImmunoTech Files Definitive Proxy Statement And Sends Letter To Shareholders
Benzinga Newsdesk
-
Nov 6, 2023, 9:28AM
Monday, October 30, 2023
AIM Immunotech Announces Abstract Accepted For Poster Presentation At The Society For Immunotherapy Of Cancer 38th Annual Meeting
Benzinga Newsdesk
-
Oct 30, 2023, 9:01AM
Tuesday, October 17, 2023
AIM ImmunoTech Engages Business Development Firm, Azenova, LLC To Catalyze Partnering, Development And Commercialization Efforts For Ampligen Pipeline Programs
Benzinga Newsdesk
-
Oct 17, 2023, 8:46AM
Monday, October 02, 2023
NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Lisa Levin
-
Oct 2, 2023, 9:07AM
Monday, September 11, 2023
Why Is Cancer Focused Microcap Stock AIM ImmunoTech Trading Higher Today?
Vandana Singh
-
Sep 11, 2023, 1:58PM
Tuesday, September 05, 2023
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights
-
Sep 5, 2023, 5:31PM
Wednesday, August 23, 2023
Why AMC Entertainment Shares Are Trading Lower By 21%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Aug 23, 2023, 8:34AM
Friday, August 18, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Aug 18, 2023, 5:32PM
Wednesday, August 16, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Aug 16, 2023, 5:32PM
Tuesday, August 15, 2023
AIM ImmunoTech Q2 EPS $(0.10) Beats $(0.11) Estimate; Cash, Cash Equivalents & Marketable Securities Of $28.4M Expected To Provide Cash Runway Into 2024
Benzinga Newsdesk
-
Aug 15, 2023, 6:47AM
Earnings Scheduled For August 15, 2023
Benzinga Insights
-
Aug 15, 2023, 4:02AM
Monday, August 14, 2023
Earnings Outlook For AIM ImmunoTech
Benzinga Insights
-
Aug 14, 2023, 12:02PM
Friday, August 11, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Aug 11, 2023, 5:31PM
Earnings Scheduled For August 11, 2023
Benzinga Insights
-
Aug 11, 2023, 7:05AM
Thursday, August 10, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Aug 10, 2023, 5:32PM
Wednesday, August 09, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Aug 9, 2023, 5:32PM
Tuesday, August 08, 2023
AIM ImmunoTech Announces Completion Of Enrollment In Phase 2 Study Evaluating Ampligen For The Treatment Of Post-COVID Conditions
Happy Mohamed
-
Aug 8, 2023, 8:28AM
Thursday, July 27, 2023
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
-
Jul 27, 2023, 5:32PM
Wednesday, July 26, 2023
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights
-
Jul 26, 2023, 5:32PM
Why PacWest Bancorp Shares Are Trading Higher By Over 35%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jul 26, 2023, 8:09AM
Tuesday, July 18, 2023
AIM ImmunoTech And 2 Other Stocks Under $1 Insiders Are Buying
Lisa Levin
-
Jul 18, 2023, 7:18AM
Friday, July 14, 2023
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights
-
Jul 14, 2023, 5:38PM
Thursday, July 13, 2023
Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
Jul 13, 2023, 8:12AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch